News &amp; Updates

Adjunctive azithromycin use during unscheduled cesarean deliveries has increased following the landmark C/SOAP trial in 2016, resulting in a decrease in postpartum infection rates in a real-world US cohort.

Azithromycin benefit in unscheduled cesarean delivery confirmed in real world

Levothyroxine offers no cardiometabolic benefits in older adults with subclinical hypothyroidism

Treatment with levothyroxine does not yield clear effects on cardiometabolic biomarkers in older adults with subclinical hypothyroidism, according to a study. However, individuals with baseline thyroid-stimulating hormone (TSH) ≥10 mIU/L show potentially favourable changes in lipids and lipoproteins.

Levothyroxine offers no cardiometabolic benefits in older adults with subclinical hypothyroidism

25 Sep 2026

Infigratinib augments Tx toolbox for achondroplasia

In the phase III PROPEL 3 trial, once-daily treatment with infigratinib results in a significantly greater increase in annualized height velocity (AHV) in children with achondroplasia.

Infigratinib augments Tx toolbox for achondroplasia

CNS-penetrant oral RIPK1 inhibitor flops for ALS

The selective, oral, central nervous system-penetrant reversible RIPK1 inhibitor SAR443820 appears to have limited clinical benefit in amyotrophic lateral sclerosis (ALS) and is even associated with greater hepatic enzyme increase, according to the phase II HIMALAYA trial.

CNS-penetrant oral RIPK1 inhibitor flops for ALS

Aficamten shows promise for nonobstructive HCM

Treatment with aficamten significantly improves patient-reported health status and exercise capacity in patients with symptomatic nonobstructive hypertrophic cardiomyopathy (nHCM), according to the ACACIA-HCM trial presented at ESC 2026.

Aficamten shows promise for nonobstructive HCM

No link between tirzepatide and atrial fibrillation, arrhythmia

Treatment with tirzepatide does not appear to be associated with atrial fibrillation or atrial arrhythmia in individuals with overweight or obesity, according to a meta-analysis.

No link between tirzepatide and atrial fibrillation, arrhythmia

Two-drug noninferior to three-drug ART as initial HIV treatment

24 Sep 2026 by

In individuals with untreated HIV-1 infection, the two-drug dolutegravir/lamivudine (DTG/3TC) antiretroviral therapy (ART) regimen has similar efficacy as the three-drug bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) regimen, according to the phase IIIb VOGUE study.

Two-drug noninferior to three-drug ART as initial HIV treatment

TSH testing patterns similar between GLP-1 RAs, SGLT-2 inhibitors in diabetes patients on levothyroxine

Patterns of thyroid-stimulating hormone (TSH) test show no substantial difference between type 2 diabetes patients treated with GLP-1 RAs and those who received SGLT-2 inhibitors, a study has found.

TSH testing patterns similar between GLP-1 RAs, SGLT-2 inhibitors in diabetes patients on levothyroxine